- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01030198
Laser Treatment for Fresh Surgical Scars and Mature Scars
December 16, 2020 updated by: Cynosure, Inc.
Post-Market, Two-Arm, Single Blind, Controlled Study of the RevLite Electro-optic Q-Switched Neodymium-doped Yttrium Aluminum Garnet (EO QS Nd:YAG) Laser System for the Treatment of Scars
The purpose of this study is to measure the effectiveness of the RevLite Laser in the treatment of both fresh surgical scars and mature/older scars.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
7
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Boca Raton, Florida, United States, 33431
- Sanctuary Medical Aesthetic Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Fitzpatrick Skin Type I-VI and either a fresh surgical scar (with sutures still present [or dissolving sutures within 7 days of surgery for facial scars or within 14 days of surgery for scars on the trunk or extremities) of at least 2cm in length or an erythematous and/or hypertrophic scar of at least 2cm in length and of greater than or equal to 18 months in duration
- Scar is easily divisible into two equal segments for the purpose of the study, or is bilateral in nature (e.g., inframammary)
Exclusion Criteria:
- Pregnant, lactating, or is planning to become pregnant
- history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins or photodermatosis
- any skin pathology/condition that could interfere with evaluation or requires the use of interfering topical systemic therapy
- coagulation disorder or currently using anti-coagulation medication (including but not limited to heavy aspirin therapy)
- any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in the study
- currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within 30 days
- unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function
- unreliable for the study, including subjects who engage in excessive alcohol intake or drug abuse, or subjects who are unable to return for scheduled follow-up visits
- Isotretinoin therapy within 6 months
- need to be exposed to artificial tanning devices or excessive sunlight during the trial
- prior treatment with parenteral gold therapy
- does not agree to refrain from other laser treatment, (micro)dermabrasion or topical scar treatment creams for the duration of the study
- Diabetes Type 1 or 2
- Lupus, scleroderma or similar immune system disorder
- underlying silicone or other non-absorbable filler in the area of the scar
- phenol chemical peel or dermabrasion to the area of the scar within 3 months
- Fitzpatrick Skin Type IV, V or VI with a known sensitivity to hydroquinone or is unwilling or unable to comply with physician/manufacturer instructions for the use of this ingredient
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fresh surgical scars
Treatment of scars
|
|
Experimental: Mature scars
Treatment of scars
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of Improvement in Scar Appearance, Vascularity, Height, Pliability, Pigmentation and Any Pre-existing Pruritis
Time Frame: 1 month post final treatment (fresh scars) or 3 and 6 months post final treatment (mature scars)
|
The number of participants who experienced improvements in scar appearance, vascularity, height, pliability, pigmentation and any pre-existing pruritis will be counted.
|
1 month post final treatment (fresh scars) or 3 and 6 months post final treatment (mature scars)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2010
Primary Completion (Actual)
December 1, 2010
Study Completion (Actual)
December 1, 2010
Study Registration Dates
First Submitted
December 10, 2009
First Submitted That Met QC Criteria
December 10, 2009
First Posted (Estimate)
December 11, 2009
Study Record Updates
Last Update Posted (Actual)
December 17, 2020
Last Update Submitted That Met QC Criteria
December 16, 2020
Last Verified
December 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C68-08-S
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Scars
-
IBSA Farmaceutici Italia SrlDerming SRLCompletedAcne Scars - Mixed Atrophic and Hypertrophic | Ice Pick Scars | Rolling Scars | Boxcar ScarsItaly
-
Cynosure, Inc.Completed
-
Innovative MedicalCompleted
-
Halscion, Inc.Completed
-
University Hospital, GhentCompleted
-
Northwestern UniversityTerminated
-
Organ, Tissue, Regeneration, Repair and ReplacementRecruiting
-
Cynosure, Inc.Completed
-
Region SkaneCompleted
-
University Hospital, GhentCompleted
Clinical Trials on RevLite (Laser Treatment)
-
ConBio, a Cynosure CompanyCompletedAcne Scars | Photodamage | Irregular PigmentationUnited States
-
Cynosure, Inc.CompletedFacial Solar LentiginesUnited States
-
Cynosure, Inc.CompletedUnwanted TattoosUnited States
-
ConBio, a Cynosure CompanyCompleted
-
University Hospital, GhentCompleted
-
Sun Yat-sen UniversityUnknownDiabetic Macular EdemaChina
-
University of California, IrvineBeckman Laser Institute University of California Irvine; Candela CorporationCompleted
-
The Metis FoundationUnited States Army Institute of Surgical ResearchCompletedHypertrophic ScarUnited States
-
Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Queen's University, BelfastRecruitingDiabetic RetinopathyChina
-
University of North Carolina, Chapel HillWithdrawn